Table 1.

Clinical and pathologic features of benign proliferative nodules

Case	Age	Sex	Site	Cytology	Melanin	H3K27me3 - IHC
1	2 weeks	F	Scalp	Epithelioid	Absent	4+
2	4 years	M	Scalp	Epithelioid	Present	4+
3	11 weeks	M	Back	Fusiform	Absent	4+
4	10 months	F	Back	Mixed	Absent	4+
5	16 months	F	Scalp	Epithelioid	Present	4+
6	4 weeks	M	Back	Fusiform	Absent	4+
7	13 years	M	Back	Epithelioid	Present	4+
8	2 years	F	Abdomen	Epithelioid	Focal	4+
9	18 years	M	Scalp	Epithelioid	Focal	4+
10	5 years	M	Back	Epithelioid	Focal	4+
11	2 years	F	Scalp	Mixed, sclerosing	Focal	4+
12	3 years	F	Leg	Mixed, sclerosing	Absent	4+
13	9 years	M	Leg	Epithelioid	Absent	4+
14	Infant	F	Scalp	Epithelioid	Present	4+
15	14 years	F	Leg	Epithelioid	Focal	4+
16	5 years	F	Leg	Epithelioid	Focal	4+
17	5 years	F	Scalp	Epithelioid	Absent	4+
18	4 weeks	M	Back	Fusiform	Absent	4+
19	6 months	F	Back	Mixed	Absent	4+
20	4 years	M	Back	Mixed	Absent	4+

M = male; F = female

3 + = 51 – 75% of tumor cells are immunoreactive

4+ = more than 75% of tumor cells are immunoreactive